Novo Nordisk Says New Obesity Drug Helps Patients Lose Weight in Mid-Stage Trial

Core Insights - The pharmaceutical giant reported that amycretin has demonstrated effectiveness in promoting weight loss and reducing diabetes in both its injection and pill formulations [1] Company Summary - The company is focusing on the dual benefits of amycretin, highlighting its potential in addressing obesity and diabetes [1]